Livforsakringsbolaget Skandia Omsesidigt Has $43,000 Stake in Quest Diagnostics Incorporated (NYSE:DGX)

Livforsakringsbolaget Skandia Omsesidigt lowered its holdings in Quest Diagnostics Incorporated (NYSE:DGX - Free Report) by 98.6% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 311 shares of the medical research company's stock after selling 21,424 shares during the quarter. Livforsakringsbolaget Skandia Omsesidigt's holdings in Quest Diagnostics were worth $43,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in DGX. NBC Securities Inc. acquired a new stake in shares of Quest Diagnostics during the 3rd quarter worth approximately $25,000. VisionPoint Advisory Group LLC grew its holdings in shares of Quest Diagnostics by 100.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 218 shares of the medical research company's stock worth $27,000 after purchasing an additional 109 shares in the last quarter. Chilton Capital Management LLC acquired a new stake in shares of Quest Diagnostics during the 1st quarter worth approximately $28,000. BKM Wealth Management LLC acquired a new stake in shares of Quest Diagnostics during the 4th quarter worth approximately $29,000. Finally, FinTrust Capital Advisors LLC grew its holdings in shares of Quest Diagnostics by 1,100.0% during the 3rd quarter. FinTrust Capital Advisors LLC now owns 264 shares of the medical research company's stock worth $32,000 after purchasing an additional 242 shares in the last quarter. Institutional investors and hedge funds own 88.06% of the company's stock.

Quest Diagnostics Price Performance

NYSE:DGX traded up $2.53 during mid-day trading on Friday, reaching $128.44. 1,557,641 shares of the company were exchanged, compared to its average volume of 826,385. Quest Diagnostics Incorporated has a 12 month low of $119.59 and a 12 month high of $148.62. The company has a fifty day moving average of $128.32 and a 200 day moving average of $130.90. The company has a quick ratio of 1.20, a current ratio of 1.31 and a debt-to-equity ratio of 0.70. The stock has a market cap of $14.26 billion, a PE ratio of 17.15, a PEG ratio of 2.77 and a beta of 0.91.

Quest Diagnostics (NYSE:DGX - Get Free Report) last announced its quarterly earnings results on Thursday, February 1st. The medical research company reported $2.15 earnings per share for the quarter, beating analysts' consensus estimates of $2.11 by $0.04. The business had revenue of $2.29 billion for the quarter, compared to the consensus estimate of $2.25 billion. Quest Diagnostics had a net margin of 9.23% and a return on equity of 15.79%. Quest Diagnostics's revenue for the quarter was down 1.9% on a year-over-year basis. During the same period last year, the company posted $1.98 EPS. On average, research analysts anticipate that Quest Diagnostics Incorporated will post 8.75 EPS for the current fiscal year.

Quest Diagnostics Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, April 22nd. Investors of record on Monday, April 8th will be given a $0.75 dividend. This represents a $3.00 dividend on an annualized basis and a dividend yield of 2.34%. This is an increase from Quest Diagnostics's previous quarterly dividend of $0.71. The ex-dividend date of this dividend is Friday, April 5th. Quest Diagnostics's dividend payout ratio (DPR) is currently 37.92%.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Truist Financial reissued a "hold" rating and set a $145.00 price objective on shares of Quest Diagnostics in a report on Wednesday, March 20th. Leerink Partnrs restated a "market perform" rating on shares of Quest Diagnostics in a research note on Monday, February 26th. Barclays initiated coverage on shares of Quest Diagnostics in a research report on Wednesday, January 3rd. They set an "equal weight" rating and a $145.00 target price for the company. StockNews.com cut shares of Quest Diagnostics from a "buy" rating to a "hold" rating in a research report on Wednesday. Finally, TheStreet cut shares of Quest Diagnostics from a "b-" rating to a "c" rating in a research report on Monday, February 5th. Ten research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $144.18.

Insider Activity at Quest Diagnostics

In other Quest Diagnostics news, EVP Catherine T. Doherty sold 821 shares of the firm's stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $126.14, for a total transaction of $103,560.94. Following the sale, the executive vice president now directly owns 70,800 shares in the company, valued at approximately $8,930,712. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Quest Diagnostics news, EVP Catherine T. Doherty sold 821 shares of the firm's stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $126.14, for a total transaction of $103,560.94. Following the sale, the executive vice president now directly owns 70,800 shares in the company, valued at approximately $8,930,712. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Michael E. Prevoznik sold 5,611 shares of the firm's stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $125.88, for a total transaction of $706,312.68. Following the sale, the senior vice president now owns 38,478 shares in the company, valued at $4,843,610.64. The disclosure for this sale can be found here. Insiders have sold 15,150 shares of company stock worth $1,913,202 in the last ninety days. Company insiders own 0.79% of the company's stock.

Quest Diagnostics Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.